JPMorgan Chase Boosts Syndax Pharmaceuticals Price Target to $45

Wall Street firm sees 85% upside potential for biotech stock

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. has increased its price target for Syndax Pharmaceuticals (NASDAQ:SNDX) from $33 to $45, representing a potential upside of 85.34% from the stock's current trading price. The investment bank maintained its "overweight" rating on the biotech company's shares.

Why it matters

This price target increase from a major Wall Street firm signals growing optimism about Syndax's drug pipeline and future growth prospects. As a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, Syndax's performance is closely watched by investors seeking exposure to the lucrative but risky biotech sector.

The details

In a research note issued on Monday, JPMorgan Chase analysts raised their price target on Syndax Pharmaceuticals from $33 to $45 and reiterated an "overweight" rating on the stock. The new $45 price target implies a potential upside of over 85% compared to Syndax's current trading price around $24 per share.

  • JPMorgan Chase issued the updated price target and rating on Monday, March 9, 2026.

The players

JPMorgan Chase & Co.

A major global investment bank and financial services firm.

Syndax Pharmaceuticals

A clinical-stage biopharmaceutical company developing novel cancer therapies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

This price target increase from a respected Wall Street firm underscores the market's growing optimism around Syndax's drug pipeline and future growth potential in the competitive cancer therapeutics space.